Regeneron Pharmaceuticals Inc (REGN)

598.54 -5.74  -0.95% NASDAQ Jun 4, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
08/06/2020 08:30 EDT Misc Regeneron Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2020
08/06/2020 Earnings Regeneron Pharmaceuticals Inc Second Quarter Earnings in 2020 Release
06/12/2020 10:30 EDT Misc Regeneron Pharmaceuticals Inc Annual General Meeting for 2019
05/05/2020 08:30 EDT Misc Regeneron Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Regeneron Pharmaceuticals Inc First Quarter Earnings Result for 2020
02/07/2020 Misc Regeneron Pharmaceuticals Inc Annual Report for 2019
02/06/2020 Earnings Regeneron Pharmaceuticals Inc Fourth Quarter Earnings for 2019 Release
02/06/2020 08:00 EST Misc Regeneron Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
11/05/2019 08:30 EST Misc Regeneron Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Regeneron Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.regeneron.com
  • Investor Relations URL: http://newsroom.regeneron.com/
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Large Cap/Growth
  • Next Earnings Release: Aug. 06, 2020
  • Last Earnings Release: May. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 7.08%
LGRCX Loomis Sayles Growth C 4.33%
XBI SPDR® S&P Biotech ETF 2.59%
AULNX American Century Ultra® G 2.29%
VGHCX Vanguard Health Care Inv 2.12%
XLV Health Care Select Sector SPDR® ETF 1.59%
ACWV iShares Edge MSCI Min Vol Global ETF 1.41%
USMV iShares Edge MSCI Min Vol USA ETF 1.40%
CFNEX American Funds Fundamental Invs 529E 1.39%
MTUM iShares Edge MSCI USA Momentum Fctr ETF 1.17%
RGEBX American Funds Growth Fund of Amer R2E 1.01%
FCNKX Fidelity® Contrafund® K 0.76%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.